OBJECTIVES: Studies have suggested that polymorphisms in genes involved in immune recognition and antigen presentation are associated with cervical cancer risk. We sought to replicate a recent study which reported an association between specific SNPs on CD83 and cervical cancer and to further explore whether effects varied by age, clinical stage (in situ versus invasive), and histology (squamous carcinomas versus adenocarcinomas). METHODS: We evaluated the association between SNPs on CD83 and cervical cancer in a multicenter case-control study of cervical cancer conducted in the Eastern United States (263 cases, 307 controls), focusing on the five SNPs (RS9296925, RS853360, RS9230, RS9370729, RS750749) previously found to be associated with cervical cancer. We also pooled data from the Eastern U.S. (263 cases) with those from the original report (377 cases) to assess the effects of CD83 on the age at diagnosis, disease stage, and histology. Risk estimates (ORs) and 95% confidence intervals were estimated using logistic regression; trend tests were performed under an additive model. RESULTS: Consistent with the original report, carriers of the CT or CC genotypes for one of the five CD83 SNPs evaluated (rs750749) demonstrated a 30% and 50% reduction in disease risk, relative to carriers of the more common TT genotype (p-trend=0.02). Two additional SNPs also resulted in consistent findings (rs9296925: p-trend=0.07 and rs9370729: p-trend=0.08), although the effects observed did not reach statistical significance at the 0.05 level. Pooled evaluation of cases from the two aforementioned studies suggested differences in the distribution of susceptibility alleles by histology; adenocarcinoma cases were more likely to be carriers of the susceptibility alleles for SNP rs9370729 (p-trend=0.02) and SNP rs750749 (p-trend=0.09). No differences were observed in the age or stage of diagnosis of carriers for CD83 susceptibility alleles relative to non-carriers. CONCLUSIONS: We confirm an association between CD83 polymorphisms and cervical cancer and suggest the possibility that CD83-disease associations might be heterogenous by tumor histology.
OBJECTIVES: Studies have suggested that polymorphisms in genes involved in immune recognition and antigen presentation are associated with cervical cancer risk. We sought to replicate a recent study which reported an association between specific SNPs on CD83 and cervical cancer and to further explore whether effects varied by age, clinical stage (in situ versus invasive), and histology (squamous carcinomas versus adenocarcinomas). METHODS: We evaluated the association between SNPs on CD83 and cervical cancer in a multicenter case-control study of cervical cancer conducted in the Eastern United States (263 cases, 307 controls), focusing on the five SNPs (RS9296925, RS853360, RS9230, RS9370729, RS750749) previously found to be associated with cervical cancer. We also pooled data from the Eastern U.S. (263 cases) with those from the original report (377 cases) to assess the effects of CD83 on the age at diagnosis, disease stage, and histology. Risk estimates (ORs) and 95% confidence intervals were estimated using logistic regression; trend tests were performed under an additive model. RESULTS: Consistent with the original report, carriers of the CT or CC genotypes for one of the five CD83 SNPs evaluated (rs750749) demonstrated a 30% and 50% reduction in disease risk, relative to carriers of the more common TT genotype (p-trend=0.02). Two additional SNPs also resulted in consistent findings (rs9296925: p-trend=0.07 and rs9370729: p-trend=0.08), although the effects observed did not reach statistical significance at the 0.05 level. Pooled evaluation of cases from the two aforementioned studies suggested differences in the distribution of susceptibility alleles by histology; adenocarcinoma cases were more likely to be carriers of the susceptibility alleles for SNP rs9370729 (p-trend=0.02) and SNP rs750749 (p-trend=0.09). No differences were observed in the age or stage of diagnosis of carriers for CD83 susceptibility alleles relative to non-carriers. CONCLUSIONS: We confirm an association between CD83 polymorphisms and cervical cancer and suggest the possibility that CD83-disease associations might be heterogenous by tumor histology.
Authors: Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland Journal: Am J Hum Genet Date: 2001-12-27 Impact factor: 11.025
Authors: J V Lacey; L A Brinton; F M Abbas; W A Barnes; P E Gravitt; M D Greenberg; S M Greene; O C Hadjimichael; L McGowan; R Mortel; P E Schwartz; S G Silverberg; A Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-12 Impact factor: 4.254
Authors: Sean F Altekruse; James V Lacey; Louise A Brinton; Patti E Gravitt; Steven G Silverberg; Willard A Barnes; Mitchell D Greenberg; Olympia C Hadjimichael; Larry McGowan; Rodrigue Mortel; Peter E Schwartz; Allan Hildesheim Journal: Am J Obstet Gynecol Date: 2003-03 Impact factor: 8.661
Authors: Robert D Burk; Masanori Terai; Patti E Gravitt; Louise A Brinton; Robert J Kurman; Willard A Barnes; Mitchell D Greenberg; Olympia C Hadjimichael; Leiping Fu; Larry McGowan; Rodrigue Mortel; Peter E Schwartz; Allan Hildesheim Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Zhengyan Zhang; Ingrid Borecki; Loan Nguyen; Duanduan Ma; Kimberly Smith; Phyllis C Huettner; David G Mutch; Thomas J Herzog; Randall K Gibb; Matthew A Powell; Perry W Grigsby; L Stewart Massad; Enrique Hernandez; Patricia L Judson; Elizabeth M Swisher; Sara Crowder; Jianduan Li; Daniela S Gerhard; Janet S Rader Journal: Cancer Res Date: 2007-12-01 Impact factor: 12.701
Authors: Colleen L Doçi; Tanmayi P Mankame; Alexander Langerman; Kelly R Ostler; Rajani Kanteti; Timothy Best; Kenan Onel; Lucy A Godley; Ravi Salgia; Mark W Lingen Journal: Int J Gynecol Pathol Date: 2012-01 Impact factor: 2.762
Authors: Clara Bodelon; Margaret M Madeleine; Lisa G Johnson; Qin Du; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz Journal: Gynecol Oncol Date: 2011-11-28 Impact factor: 5.482
Authors: Xiaoxia Hu; Zhengyan Zhang; Duanduan Ma; Phyllis C Huettner; L Stewart Massad; Loan Nguyen; Ingrid Borecki; Janet S Rader Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-03 Impact factor: 4.254
Authors: Duanduan Ma; Raymond L Hovey; Zhengyan Zhang; Samantha Fye; Phyllis C Huettner; Ingrid B Borecki; Janet S Rader Journal: Gynecol Oncol Date: 2013-08-06 Impact factor: 5.482
Authors: Paul J Leo; Margaret M Madeleine; Sophia Wang; Stephen M Schwartz; Felicity Newell; Ulrika Pettersson-Kymmer; Kari Hemminki; Goran Hallmans; Sven Tiews; Winfried Steinberg; Janet S Rader; Felipe Castro; Mahboobeh Safaeian; Eduardo L Franco; François Coutlée; Claes Ohlsson; Adrian Cortes; Mhairi Marshall; Pamela Mukhopadhyay; Katie Cremin; Lisa G Johnson; Cornelia L Trimble; Suzanne Garland; Sepehr N Tabrizi; Nicolas Wentzensen; Freddy Sitas; Julian Little; Maggie Cruickshank; Ian H Frazer; Allan Hildesheim; Matthew A Brown Journal: PLoS Genet Date: 2017-08-14 Impact factor: 5.917
Authors: Alireza Torabi; Javier Ordonez; Brenda Bin Su; Laura Palmer; Chunxiang Mao; Katherine E Lara; Lewis P Rubin; Chun Xu Journal: Med Sci (Basel) Date: 2016-08-03